Welcome to our dedicated page for Oncocyte Corporation news (Ticker: OCX), a resource for investors and traders seeking the latest updates and insights on Oncocyte Corporation stock.
Oncocyte Corporation (OCX) is a pioneering precision diagnostics company dedicated to the discovery, development, and commercialization of non-invasive, liquid biopsy diagnostics aimed at facilitating clinical decision-making in the early detection of cancer. The company focuses on molecular tests that address high unmet needs in the diagnosis of lung, breast, and bladder cancers, conditions where current diagnostic standards are often ambiguous, costly, and invasive. Oncocyte's tests are developed based on a proprietary set of biomarkers, designed to differentiate between benign and malignant nodules or masses.
Oncocyte’s flagship products include:
- DetermaIO™: A gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
- DetermaCNI™: A blood-based monitoring tool for therapeutic efficacy in cancer patients.
- VitaGraft™: A blood-based solid organ transplantation monitoring test.
- GraftAssure™: A research-use-only monitoring test for solid organ transplantation.
The company has made significant strides in expanding its diagnostic capabilities and achieving key regulatory and commercial milestones. In 2023, Oncocyte secured reimbursement for VitaGraft™ Kidney, manufactured the initial lots of GraftAssure RUO, and entered a strategic partnership with Bio-Rad Laboratories to commercialize GraftAssure and develop VitaGraft Kidney IVD. This partnership, along with a successful $15.8 million private placement offering, positions Oncocyte well to meet its critical commercial and regulatory goals.
Oncocyte continues to be supported by strong core investors and aims to provide clarity and confidence to physicians and their patients through its groundbreaking diagnostic tests. For more information, visit www.oncocyte.com.
Oncocyte Corporation (NYSE American: OCX) has priced an underwritten public offering of 7,780,000 shares at $4.50 each, expected to generate approximately $35 million in gross proceeds. Set to close around February 9, 2021, the offering includes a 30-day option for underwriters to purchase an additional 1,167,000 shares. Funds will be utilized for the commercialization of DetermaRx™, development of DetermaIO™, future tests, and potential acquisitions, including a merger with Chronix Biomedical. The offering is conducted under a shelf registration statement effective June 18, 2019.
Oncocyte Corporation (NYSE American: OCX) has announced an underwritten public offering of its common stock. The offering will include an option for underwriters to purchase an additional 15% of shares. Proceeds from this offering are intended to support the commercialization of the DetermaRx™ diagnostic test, complete development of DetermaIO™, and fund future tests, including the CNI Monitor test through a merger with Chronix Biomedical. The offering is subject to market conditions and the actual terms may vary.
Oncocyte Corporation (NYSE American: OCX) has announced the presentation of a scientific poster on its DetermaRx™ test at the IASLC 2020 World Conference on Lung Cancer. The test, which identifies early-stage lung cancer patients who may benefit from adjuvant chemotherapy, has seen broad adoption across 80 hospitals. Analysis from 250 cases shows it reclassifies 19% of patients without high-risk features as high/intermediate risk, indicating its clinical utility. DetermaRx demonstrated improved survival rates of 92% in treated patients, underscoring its significance in lung cancer management.
Oncocyte Corporation (OCX) announced a registered offering of approximately $25 million in common shares priced at $3.424 each. This offering is led by existing investor Pura Vida Investments and Broadwood Partners, increasing Pura Vida's stake to around 16%. The funds will bolster Oncocyte's balance sheet, facilitating the launch of DetermaIO and DetermaTX while supporting ongoing cancer diagnostics development. After this offering, Oncocyte expects to have over $37 million in cash. The offering is anticipated to close during the week of January 26, 2021.
Oncocyte Corporation (NYSE American: OCX) announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 15, 2021, at 10:45 AM EST. The conference aims to provide a platform for the company to present its advancements in molecular diagnostics, particularly in cancer care. Investors can register for the conference through the provided link and access a replay of the presentation on Oncocyte's website post-event. The company's innovative products, such as DetermaRx™ for lung cancer recurrence and DetermaIO™ for immunotherapy response, are integral to its mission of enhancing cancer treatment outcomes.
Oncocyte Corporation (NYSE American: OCX) announced its participation in the 13th Annual LD Micro Main Event Conference on December 15, 2020. The company will present from 12:40 PM to 1:00 PM EST. Investors can register for the event online. Following the presentation, a replay will be available on Oncocyte's investor website. Oncocyte focuses on providing actionable diagnostics across the cancer care continuum, with products like DetermaRx™, which identifies high-risk lung cancer patients, and DetermaIO™, assessing tumor responses to immunotherapies.
Oncocyte has signed an exclusive licensing agreement with Burning Rock Biotech in China for its DetermaRx test, which identifies high-risk early-stage lung cancer patients. The agreement includes payments of up to $6M in the first year, and ongoing royalties per test. The technology transfer is expected in Q1 2021, with installation by Q3. This marks Oncocyte's fifth global licensing agreement, enhancing its presence in a major market for early-stage lung cancer, with significant potential for revenue growth and improved patient outcomes.
Oncocyte Corporation (NYSE American: OCX) will host a key opinion leader call on December 15, 2020, featuring discussions on its proprietary tests, DetermaRx™ and DetermaIO™, for cancer treatment selection. Key opinion leaders from UCSF and Yale Cancer Center will present their clinical applications and evidence. The company identifies a combined market opportunity exceeding $3 billion for these tests, which aim to enhance patient outcomes and reduce healthcare costs.
Oncocyte Corporation (NYSE American: OCX) will participate in the Piper Sandler Virtual Healthcare Conference on December 1, 2020, for 1-on-1 meetings. The company's mission is to enhance cancer care through molecular diagnostics with tools like DetermaRx, a test for early-stage lung cancer patients to identify recurrence risk, and DetermaIO, aimed at predicting immunotherapy responses. These innovations seek to improve patient outcomes by providing critical information at key decision points in cancer treatment.
Oncocyte Corporation (OCX) presented data on its DetermaIO™ test at the AMP 2020 Virtual Conference. This CLIA validated test utilizes real-time PCR to assess 27 genes, predicting responses to immune checkpoint inhibitors in non-small cell lung cancer and triple-negative breast cancer. Data show DetermaIO requires as little as 2mm2 of tissue, significantly less than other tests. This advancement may increase patient eligibility for immunotherapy and improve clinical decision-making. Oncocyte aims to launch DetermaIO for clinical use, enhancing cancer diagnosis and therapy options.
FAQ
What is the current stock price of Oncocyte Corporation (OCX)?
What is the market cap of Oncocyte Corporation (OCX)?
What does Oncocyte Corporation specialize in?
What types of cancer does Oncocyte's diagnostics target?
What are some of Oncocyte's key products?
How does Oncocyte's DetermaIO™ test work?
What recent achievements has Oncocyte made?
Who are some of Oncocyte's partners?
What is the purpose of Oncocyte's VitaGraft™ test?
What is GraftAssure™ used for?
How does Oncocyte support its operations financially?
Where can I find more information about Oncocyte Corporation?
